Literature DB >> 34004187

Targeted protein degradation: A promise for undruggable proteins.

Kusal T G Samarasinghe1, Craig M Crews2.   

Abstract

Protein homeostasis, or "proteostasis," is indispensable for a balanced, healthy environment within the cell. However, when natural proteostasis mechanisms are overwhelmed from excessive loads of dysregulated proteins, their accumulation can lead to disease initiation and progression. Recently, the induced degradation of such disease-causing proteins by heterobifunctional molecules, i.e., PROteolysis TArgeting Chimeras (PROTACs), is emerging as a potential therapeutic modality. In the 2 decades since the PROTAC concept was proposed, several additional Targeted Protein Degradation (TPD) strategies have also been explored to target previously undruggable proteins, such as transcription factors. In this review, we discuss the progress and evolution of the TPD field, the breadth of the proteins targeted by PROTACs and the biological effects of their degradation.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PROTACs; proteasome; targeted protein degradation; ubiquitination; undruggable proteome

Mesh:

Substances:

Year:  2021        PMID: 34004187      PMCID: PMC8286327          DOI: 10.1016/j.chembiol.2021.04.011

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   9.039


  178 in total

Review 1.  Genome engineering with zinc-finger nucleases.

Authors:  Dana Carroll
Journal:  Genetics       Date:  2011-08       Impact factor: 4.562

2.  A caged E3 ligase ligand for PROTAC-mediated protein degradation with light.

Authors:  Cyrille S Kounde; Maria M Shchepinova; Charlie N Saunders; Marcel Muelbaier; Mark D Rackham; John D Harling; Edward W Tate
Journal:  Chem Commun (Camb)       Date:  2020-04-16       Impact factor: 6.222

Review 3.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

4.  Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα).

Authors:  Peter S Dragovich; Pragya Adhikari; Robert A Blake; Nicole Blaquiere; Jinhua Chen; Yun-Xing Cheng; Willem den Besten; Jinping Han; Steven J Hartman; Jintang He; Mingtao He; Ellen Rei Ingalla; Amrita V Kamath; Tracy Kleinheinz; Tommy Lai; Douglas D Leipold; Chun Sing Li; Qi Liu; Jiawei Lu; Ying Lu; Fanwei Meng; Lingyao Meng; Carl Ng; Kaishan Peng; Gail Lewis Phillips; Thomas H Pillow; Rebecca K Rowntree; Jack D Sadowsky; Deepak Sampath; Leanna Staben; Steven T Staben; John Wai; Kunpeng Wan; Xinxin Wang; BinQing Wei; Ingrid E Wertz; Jianfeng Xin; Keyang Xu; Hui Yao; Richard Zang; Donglu Zhang; Hao Zhou; Yongxin Zhao
Journal:  Bioorg Med Chem Lett       Date:  2019-12-18       Impact factor: 2.823

Review 5.  STAT3 inhibitors for cancer therapy: Have all roads been explored?

Authors:  Remi Fagard; Valeri Metelev; Inès Souissi; Fanny Baran-Marszak
Journal:  JAKSTAT       Date:  2013-01-01

6.  An enhanced CRISPR repressor for targeted mammalian gene regulation.

Authors:  Nan Cher Yeo; Alejandro Chavez; Alissa Lance-Byrne; Yingleong Chan; David Menn; Denitsa Milanova; Chih-Chung Kuo; Xiaoge Guo; Sumana Sharma; Angela Tung; Ryan J Cecchi; Marcelle Tuttle; Swechchha Pradhan; Elaine T Lim; Noah Davidsohn; Mo R Ebrahimkhani; James J Collins; Nathan E Lewis; Samira Kiani; George M Church
Journal:  Nat Methods       Date:  2018-07-16       Impact factor: 28.547

Review 7.  Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.

Authors:  Michael J Bond; Craig M Crews
Journal:  RSC Chem Biol       Date:  2021-03-19

8.  Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer.

Authors:  Peng Kuang; Zuhua Chen; JiaYuan Wang; Zhentao Liu; Jingyuan Wang; Jing Gao; Lin Shen
Journal:  Transl Oncol       Date:  2017-04-18       Impact factor: 4.243

9.  DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.

Authors:  Yonghan He; Raphael Koch; Vivekananda Budamagunta; Peiyi Zhang; Xuan Zhang; Sajid Khan; Dinesh Thummuri; Yuma T Ortiz; Xin Zhang; Dongwen Lv; Janet S Wiegand; Wen Li; Adam C Palmer; Guangrong Zheng; David M Weinstock; Daohong Zhou
Journal:  J Hematol Oncol       Date:  2020-07-16       Impact factor: 17.388

10.  Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer.

Authors:  Matthew G Costales; Haruo Aikawa; Yue Li; Jessica L Childs-Disney; Daniel Abegg; Dominic G Hoch; Sai Pradeep Velagapudi; Yoshio Nakai; Tanya Khan; Kye Won Wang; Ilyas Yildirim; Alexander Adibekian; Eric T Wang; Matthew D Disney
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-21       Impact factor: 11.205

View more
  8 in total

Review 1.  Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras.

Authors:  Chunlong Zhao; Frank J Dekker
Journal:  ACS Pharmacol Transl Sci       Date:  2022-08-22

2.  New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Pharmacology & Translational Science.

Authors:  Christa E Müller; Finn K Hansen; Michael Gütschow; Craig W Lindsley; Dennis Liotta
Journal:  ACS Med Chem Lett       Date:  2021-09-30       Impact factor: 4.632

3.  New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Pharmacology & Translational Science.

Authors:  Christa E Müller; Finn K Hansen; Michael Gütschow; Craig W Lindsley; Dennis Liotta
Journal:  ACS Pharmacol Transl Sci       Date:  2021-09-30

4.  A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions.

Authors:  Le Guo; Yaxian Zhou; Xueqing Nie; Zhongrui Zhang; Zhen Zhang; Chunrong Li; Taobo Wang; Weiping Tang
Journal:  Eur J Med Chem       Date:  2022-04-01       Impact factor: 7.088

Review 5.  Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.

Authors:  Matthew R Burke; Alexis R Smith; Guangrong Zheng
Journal:  Front Cell Dev Biol       Date:  2022-04-25

Review 6.  Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles.

Authors:  Alberto Juan; María Del Mar Noblejas-López; María Arenas-Moreira; Carlos Alonso-Moreno; Alberto Ocaña
Journal:  Front Cell Dev Biol       Date:  2022-02-03

Review 7.  Key Considerations in Targeted Protein Degradation Drug Discovery and Development.

Authors:  Liena Qin; Han Dai; Junfeng Wang
Journal:  Front Chem       Date:  2022-08-01       Impact factor: 5.545

Review 8.  Targeting NRF2 to treat cancer.

Authors:  Jared Sivinski; Donna D Zhang; Eli Chapman
Journal:  Semin Cancer Biol       Date:  2021-06-05       Impact factor: 15.707

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.